Autolus Therapeutics AUTL
Autolus Therapeutics reported a $55.09 million net loss
Autolus Therapeutics (AUTL) filed a 10-Q with the SEC on Nov 10, 2026, 4:48 pm ET. Source: the filing on SEC EDGAR.
- Form
- 10-Q
- Filed
- Importance
- Notable
- Accession
- 0001730463-26-000148
- Revenue of $41.24 million for the three months ended Sep 30, 2026
- Net loss of $55.09 million for the three months ended Sep 30, 2026
- Cash and equivalents of $245.41 million as of Sep 30, 2026
Written from the 10-Q on EDGAR. AI can make mistakes. Check the filing.
What changed since last quarter
1 new risk factor
Compared with the 10-Q for the period ended Jun 30, 2026.
| This filing | Previous | Change vs prior 10-Q | |
|---|---|---|---|
| Revenue | $41.24M | $45.69M | −9.7% |
| Operating income and margin | −$43.54M · -105.6% | −$43.84M · -95.9% | +0.7%, margin −9.7 pts |
| Net income | −$55.09M | −$39.11M | −41% |
| Operating cash flow | −$18.53M | −$25.07M | +26% |
| Cash | $245.41M | $171.41M | +43% |
New risk factors (1)
- Our obligations under the Notes Facility are secured by substantially all of our assets and are subject to financial covenants, and a failure to comply with those covenants could have a material adverse effect on our business. +3 more paragraphs